| Project/Area Number |
13226058
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | Osaka University |
|---|
Principal Investigator |
HORII Toshihiro OSAKA UNIVERSITY, RESEARCH INSTITUTE FOR MICROBIAL DISEASES, PROFESSOR, 微生物病研究所, 教授 (80142305)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
ARISUE Nobuko OSAKA UNIVERSITY, RESEARCH INSTITUTE FOR MICROBIAL DISEASES, RESEARCH ASSOCIATE, 微生物病研究所, 助手 (00242339)
TAI Kumiko OSAKA UNIVERSITY, RESEARCH INSTITUTE FOR MICROBIAL DISEASES, TECHNICAL OFFICIAL, 微生物病研究所, 教務職員 (00187907)
ISHIBASHI Masahide THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY, KAN-ON,JI INSTITUTE, DIRECTOR, 観音寺研究所, 所長(研究職) (70029776)
KAWAMOTO Fumihiko OITA UNIVERSITY, INSTITUTE OF SCIENTIFIC RESEARCH, PROFESSOR, 総合科学研究支援センター, 教授 (40115556)
MATSUMOTO Yoshitsugu THE UNIVERSITY OF TOKYO, GRADUATE SCHOOL OF AGRICULTURAL AND LIFE SCIENCES, ASSOCIATE, PROFESSOR, 大学院・農学生命科学研究科, 助教授 (00173922)
三田村 俊秀 大阪大学, 微生物病研究所, 助教授 (80268846)
李 接 大阪大学, 微生物病研究所, 助手 (50333505)
|
|---|
| Project Period (FY) |
2001 – 2005
|
| Project Status |
Completed (Fiscal Year 2005)
|
| Budget Amount *help |
¥56,000,000 (Direct Cost: ¥56,000,000)
Fiscal Year 2005: ¥15,000,000 (Direct Cost: ¥15,000,000)
Fiscal Year 2004: ¥15,000,000 (Direct Cost: ¥15,000,000)
Fiscal Year 2003: ¥16,000,000 (Direct Cost: ¥16,000,000)
Fiscal Year 2002: ¥10,000,000 (Direct Cost: ¥10,000,000)
|
|---|
| Keywords | Malaria Vaccine / SE36 Protein / P falciparum / clinical research / enidemiological research / P vivax / SERA gene / Sauirrel monke / P.falciparum / P.vivax / ソロモン諸島 / 前臨床試験 / SERA遺伝子発現 / SERA遺伝子ファミリー / SERAプロセッシング / 感染赤血球膜壊裂 |
|---|
| Research Abstract |
We have been developing an effective malaria vaccine by using a recombinant SE36 protein, N-terminal domain of Serine Repeat Antigen (SERA5) of Plasmodium falcaprum. Cross sectional field studies have been conducted to evaluate the contribution of naturally acquired immunity of SE36 protein in malaria protection and shown that a strong negative correlations between anti-SE36 IgG3 titer and both of the symptoms and blood parasitemia. In addition, we found that sero-conversion rates against SE36 were 50% or less in adults and less than 10% in younger generations in the cohorts. These findings strongly suggest that N-terminal domain of SERA is a hidden protective antigen like as Achilles heel of malaria parasite.
The clinical grade BK-SE36, the purified SE36 protein adsorbed to aluminum hydroxide gel, prepared under GMP conditions was safe and highly immunogenic in Chimpanzees. In addition, the product provided significant protection in Squirrel monkeys after P falciparum challenge infection. The antibody titers in immunized monkeys were boosted by the challenge infection. Safety and Immunogenicity of BK-SE36 were confirmed in Phase I clinical trial in Japan.
|
